- About 40% of U.S. adults have obesity, but only 19% of large employer plans cover anti-obesity medications (as of 2024 data)
- A weight loss plan exclusion is different from a formulary restriction or prior authorization denial
- Alternative FDA indications (cardiovascular, sleep apnea) may provide coverage pathways even with an exclusion
- Open enrollment is your annual opportunity to switch to a plan that covers the medications you need
What is a weight loss exclusion?
A weight loss plan exclusion is a clause in your insurance policy that specifically excludes coverage for medications, procedures, or services used primarily for weight loss. When this exclusion is present, your insurer will not cover anti-obesity medications — regardless of how medically necessary they are for your health.
This means medications like Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), and Contrave (naltrexone/bupropion) are all categorically excluded. BMI qualification, comorbidities, and even strong prior authorization documentation do not override the exclusion. The exclusion overrides everything.
Approximately 40% of U.S. adults have obesity, a recognized chronic disease. Yet as of 2025, only about 19% of large employer-sponsored plans cover anti-obesity medications (as of 2024 data). The gap between the clinical consensus (obesity is a disease requiring treatment) and insurance policy (weight loss is optional) remains one of the largest barriers to care.
Weight loss exclusions are not the same as a prior authorization denial or a formulary restriction. Those can be appealed. An exclusion is a structural feature of your plan design — it is baked into the policy itself.
Why these exclusions exist
Weight loss plan exclusions are primarily a cost containment strategy. Anti-obesity medications are expensive, and if every eligible employee in a plan used them, the cost to the employer or insurer would be substantial. Exclusions allow plan sponsors to control this exposure.
There is also a historical dimension. For decades, obesity was not widely recognized as a chronic disease by insurers. Weight loss was considered a lifestyle choice, not a medical need. Although the medical community — including the American Medical Association, the Obesity Medicine Association, and the Endocrine Society — now classifies obesity as a chronic disease, insurance policies have been slow to catch up.
Insurance policy still lags behind medical science by a decade. Obesity has been recognized as a disease since 2013. Most plans still treat it as a preference.
The introduction of GLP-1 medications has accelerated this tension. With medications that produce 15–22% body weight loss now available, demand has surged — and so has the financial pressure on plan sponsors. Some employers are adding coverage; others are reinforcing exclusions to limit liability.
How to know if your plan has one
Checking for a weight loss exclusion requires looking at your actual plan documents, not just calling your insurer. Here is how to find out:
- Check your Summary of Benefits and Coverage (SBC). This document is required by law and should be available through your HR department or your insurer’s member portal. Look for a section on excluded services.
- Search your full plan document. Look for language like “weight loss medications excluded,” “anti-obesity drugs not covered,” “weight management services excluded,” or “medications for weight reduction are not a covered benefit.”
- Check the formulary. If the medication does not appear on your formulary at all, that is a strong signal — but it is not the same as an exclusion. It could mean the plan has simply not added it yet, or that it requires an exception.
- Call the number on your card. Ask directly: “Does my plan have a weight loss medication exclusion?” Get the answer in writing if possible.
- Ask PEAK to verify. Our insurance team checks for exclusions as part of our standard benefits verification process. We can tell you exactly what your plan covers before you start treatment.
Exclusion vs. formulary vs. PA denial
Understanding the difference between these three types of coverage barriers is critical because the response to each is completely different:
What it means: Your plan categorically does not cover weight loss medications. No appeal, PA, or clinical argument will change this for the current plan year.
What you can do: Explore alternative coverage pathways (non-weight-loss indications), manufacturer programs, or plan changes at open enrollment.
What it means: Your plan covers some weight loss medications but not the specific one prescribed. The medication is not on the plan’s approved drug list.
What you can do: Your clinician can request a formulary exception, prescribe an alternative that is on formulary, or submit additional clinical justification.
What it means: Your plan covers the medication, but the PA submission did not meet the insurer’s criteria. This is the most fixable of the three.
What you can do: Resubmit with additional documentation, request a peer-to-peer review, or file a formal appeal.
Option 1: The cardiovascular indication
In March 2024, the FDA expanded Wegovy’s approved indication to include reduction of cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight. This was based on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events.
This matters for patients with weight loss exclusions because the medication is now being prescribed for a cardiovascular purpose, not a weight loss purpose. Some plans that exclude weight loss medications will cover Wegovy when prescribed under the cardiovascular indication — because the coverage pathway is cardiology, not obesity medicine.
You must have established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) and a BMI of 27 or higher. Your clinician documents the prescription under the cardiovascular indication, and your insurer evaluates it through their cardiology coverage criteria rather than their weight loss exclusion.
Option 2: The sleep apnea indication
In late 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Like the cardiovascular indication for Wegovy, this creates a separate clinical and insurance pathway.
If you have a documented sleep apnea diagnosis confirmed by a sleep study, your clinician may prescribe Zepbound under the OSA indication. Plans that exclude weight loss medications may still cover medications prescribed for sleep apnea treatment, since OSA is not classified as a weight loss condition.
This is not a workaround. OSA is a serious medical condition, and tirzepatide has been shown to significantly improve it. If you have both obesity and sleep apnea, this pathway treats both conditions simultaneously while potentially working around the weight loss exclusion.
Option 3: The diabetes pathway
If you have type 2 diabetes or prediabetes, your clinician may prescribe a GLP-1 medication under the diabetes indication. Semaglutide (marketed as Ozempic for diabetes) and tirzepatide (marketed as Mounjaro for diabetes) are the same active ingredients as Wegovy and Zepbound, but prescribed under different brand names for a different condition.
Weight loss exclusions typically do not apply to diabetes medications. If your plan covers Ozempic or Mounjaro for diabetes management, you may be able to access the medication through that pathway — even if the same ingredient is excluded when prescribed specifically for weight loss.
This pathway requires a genuine diabetes or prediabetes diagnosis. Your clinician must document the appropriate A1C levels, fasting glucose, or other diagnostic criteria. At PEAK, we evaluate every patient’s full metabolic profile. If diabetes or prediabetes is present, we use the most clinically appropriate pathway.
Option 4: Manufacturer savings programs
Both Eli Lilly (Zepbound) and Novo Nordisk (Wegovy) offer savings programs that can reduce out-of-pocket costs for patients whose insurance does not cover these medications. These programs have eligibility requirements and limitations, but they are worth exploring.
- Eli Lilly’s Zepbound savings card — Available to commercially insured patients. Can reduce monthly costs significantly for eligible patients.
- Novo Nordisk’s Wegovy savings program — Similar structure. Eligibility varies by insurance status.
- Patient assistance programs — For patients without insurance or with very limited coverage, manufacturers sometimes offer patient assistance programs with reduced or no-cost medication.
These programs change frequently. PEAK’s team stays current on available programs and can help you determine whether you qualify.
Option 5: Open enrollment plan changes
If your current plan has a weight loss exclusion and none of the alternative pathways apply to you, open enrollment is your annual opportunity to switch to a plan that covers the medications you need.
Here is how to approach it:
- Review available plans. During open enrollment, compare the formularies of all available plan options. Look specifically for anti-obesity medication coverage.
- Ask HR directly. If you have an employer-sponsored plan, ask your benefits team whether any available plan options cover weight loss medications. Some employers offer multiple plan tiers with different formularies.
- Consider the total cost. A plan that covers GLP-1 medications may have a higher monthly premium, but if it substantially lowers medication costs, the math often works in your favor.
- Advocate for change. If none of your employer’s plan options cover anti-obesity medications, consider speaking with your HR department or benefits committee. Employers are increasingly hearing from employees about this gap, and some are adding coverage in response to demand.
Open enrollment typically happens in the fall for a January 1 start date. If you know you want to pursue GLP-1 medication, start researching your options before enrollment opens. PEAK can help you evaluate your plan options and understand which ones are most likely to cover the treatment you need.
Important safety information: Wegovy and Zepbound carry a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. They are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Contrave carries a boxed warning for suicidal thoughts and behavior. Discuss your full medical history with your clinician before starting any weight loss medication.
PEAK accepts commercial insurance and TRICARE. We do not accept Medicare or Medicaid, including Medicare Advantage and Medicaid managed care plans.
